N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition

Figure 2

AcSDKP exerts antifibrotic effects on diabetic kidney disease. ((a)–(e)) Representative periodic acid Schiff- (PAS-) stained kidney samples from the indicated groups of mice. The original magnification of the images was 300x. ((f)–(j)) Representative images of Masson’s trichrome-stained (MTS) samples from the indicated groups of mice are shown. The original magnification of the images was 200x. ((k)–(m)) Morphometric analysis. The glomerular surface area (k), relative mesangial area (l), and relative area of fibrosis (m) were analyzed by the method described in the Methods section. (n) Urinary albumin/creatinine ratio. The data are expressed as the mean ± SEM values. Control: 𝑛=7, STZ-induced diabetes: 𝑛=5, diabetes treated with imidapril: 𝑛=6, diabetes treated with imidapril+AcSDKP: 𝑛=5, diabetes treated with TA-606: 𝑛=3. Diabetic mice are designated as DM. Scale bar: 50 μm.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)